Attendees of the 6th ISVHLD Global Hepatitis Summit in June in Toronto will have the opportunity to benefit from AASLD’s expertise during a daylong Hepatocellular Carcinoma (HCC) Symposium on Friday, June 15, and a special Pan-American Symposium on viral hepatitis on Thursday, June 14.
In this issue of the AASLD News, the HCC Symposium will be highlighted. Look for details about the Pan-American Symposium in the April 19 issue of AASLD News.
The Global Hepatitis Summit, or International Symposium on Viral Hepatitis and Liver Disease (ISVHLD), brings together experts from around the world for four days of meetings, abstracts, symposia and networking. AASLD members have long been involved in participating in the meeting as sponsors, presenters and organizers. However, this year, AASLD joins EASL and ISVHLD in presenting an in-depth symposium specifically focused on HCC, according to Adrian Di Bisceglie, MD, FAASLD, former AASLD President and co-director of the Saint Louis University Liver Center.
“HCC is a problem in the Americas and Asia and Europe. It is a problem with an international face to it,” said Dr. Di Bisceglie, who has served on the Summit committee for a number of years. “HCC is a consequence of underlying liver disease, whether it be from viral hepatitis or cirrhosis. So, the symposium is an opportunity for the three organizations to work together on something.”
The symposium, which is included in the full meeting registration or as a special one-day program, is divided into three sessions. The first will cover the broad implications of HCC, with speakers addressing global epidemiology, genetic and epigenetic factors of HCC, HCC surveillance and strategies to improve healthcare delivery.
Session two will focus specifically on hepatitis B (HBV) and HCC with four speakers covering oncogenesis, epidemiology, and risk factors of HBV-related HCC, as well as development of HCC in patients with suppressed viral replication. Session three, focused on hepatitis C (HCV) and HCC, will cover risk before and after HCV treatment, treatment challenges and transplantation issues.
“This is one of the cancers that best exemplifies multidisciplinary treatment approaches,” said Dr. Di Bisceglie, noting that the disease involves a number of medical stakeholders including hepatologists, liver surgeons, liver transplant surgeons, interventional radiologists, medical oncologists, diagnostic radiologists and pathologists.
It’s particularly important to bring together these stakeholders because the number of cases continues to grow worldwide as one of the major causes of lethal cancer in adults, he added.
For more information about the Summit or to register for either the Summit or the HCC Symposium, click here.